Cara Therapeutics is a biotechnology business based in the US. Cara Therapeutics stocks (CARA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.66 – an increase of 3.04% over the previous week. Cara Therapeutics employs 80 staff and has a trailing 12-month revenue of around $123.3 million.
How to buy shares in Cara Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CARA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Cara Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Cara Therapeutics?
- Has coronavirus impacted Cara Therapeutics shares?
- Cara Therapeutics shares summary
- Compare share dealing platforms
- Is Cara Therapeutics stock a buy or sell?
- Cara Therapeutics performance over time
- Can I short Cara Therapeutics shares?
- Are Cara Therapeutics shares over-valued?
- Cara Therapeutics's financials
- How volatile are Cara Therapeutics shares?
- Does Cara Therapeutics pay a dividend?
- Have Cara Therapeutics shares ever split?
- Other common questions
How has Coronavirus impacted Cara Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Cara Therapeutics's stock price has had significant negative movement.
Its last market close was $13.22, which is 23.27% down on its pre-crash value of $17.23 and 48.87% up on the lowest point reached during the March crash when the stocks fell as low as $8.88.
If you had bought $1,000 worth of Cara Therapeutics stocks at the start of February 2020, those stocks would have been worth $678.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $810.52.
Cara Therapeutics stock priceUse our graph to track the performance of CARA stocks over time.
Cara Therapeutics shares at a glance
|Latest market close||$13.22|
|52-week range||$11.22 - $29.65|
|50-day moving average||$14.62|
|200-day moving average||$15.43|
|Wall St. target price||$25.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.17|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Cara Therapeutics price performance over time
|1 week (2021-10-19)||3.04%|
|1 month (2021-09-24)||-17.01%|
|3 months (2021-07-26)||9.53%|
|6 months (2021-04-26)||-50.13%|
|1 year (2020-10-26)||-5.10%|
|2 years (2019-10-25)||-34.10%|
|3 years (2018-10-26)||18.67|
|5 years (2016-10-26)||87.25%|
Is Cara Therapeutics under- or over-valued?
Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cara Therapeutics's P/E ratio
Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 75x. In other words, Cara Therapeutics shares trade at around 75x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cara Therapeutics's EBITDA
Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.1 million.
The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.
Cara Therapeutics financials
|Revenue TTM||$123.3 million|
|Operating margin TTM||5.54%|
|Gross profit TTM||$27.2 million|
|Return on assets TTM||2.19%|
|Return on equity TTM||4.85%|
|Market capitalisation||$636.1 million|
TTM: trailing 12 months
Shorting Cara Therapeutics shares
There are currently 2.1 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 30.2% down from 3.0 million last month.
There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.
Cara Therapeutics's "short interest ratio" (SIR)
Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 813307.27969349). Cara Therapeutics's SIR currently stands at 2.61. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 2610 shares are currently held short.
However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0432% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.
Cara Therapeutics share dividends
We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.
Have Cara Therapeutics's shares ever split?
Cara Therapeutics's shares were split on a 1:2 basis on 16 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.
Cara Therapeutics share price volatility
Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $11.22 up to $29.6473. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.1302. This would suggest that Cara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cara Therapeutics overview
Cara Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co.
Stocks similar to Cara Therapeutics
Frequently asked questions
Cara Therapeutics in the news
Are Cara Therapeutics, Inc.'s (NASDAQ:CARA) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Investing in Cara Therapeutics (NASDAQ:CARA) five years ago would have delivered you a 69% gain
Cara Therapeutics : Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
How to buy Fluence Energy (FLNC) stock in Canada when it goes public
Everything we know about the Fluence Energy IPO, plus information on how to buy in.
How to buy GlobalFoundries (GFS) stock in Canada when it goes public
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
How to buy LianBio (LIAN) stock in Canada when it goes public
Everything we know about the LianBio IPO, plus information on how to buy in.
How to buy Rent the Runway (RENT) stock in Canada when it goes public
Everything we know about the Rent the Runway IPO, plus information on how to buy in.
How to buy Solo Brands (DTC) stock in Canada when it goes public
Everything we know about the Solo Brands IPO, plus information on how to buy in.
How to buy Udemy (UDMY) stock in Canada when it goes public
Everything we know about the Udemy IPO, plus information on how to buy in.
How to buy Arteris (AIP) stock in Canada when it goes public
Everything we know about the Arteris IPO, plus information on how to buy in.